


LETTER

Open Access



Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial

Florence Carrouel^{1*} , Stéphane Viennot¹, Martine Valette², Jean-Marie Cohen³, Claude Dussart¹ and Denis Bourgeois¹

Abstract

Objectives: - To describe the evolution of the SARS-CoV-2 salivary viral load of patients infected with Covid-19, performing 7 days of tri-daily mouthwashes with and without antivirals.

- To compare the evolution of the SARS-CoV-2 nasal and salivary viral load according to the presence or absence of antivirals in the mouthwash.

Trial design: This is a multi-center, randomised controlled trial (RCT) with two parallel arms (1:1 ratio).

Participants: Inclusion criteria

- Age: 18-85 years old
- Clinical diagnosis of Covid-19 infection
- Clinical signs have been present for less than 8 days
- Virological confirmation
- Understanding and acceptance of the trial
- Written agreement to participate in the trial

Exclusion criteria

- Pregnancy, breastfeeding, inability to comply with protocol, lack of written agreement - Patients using mouthwash on a regular basis (more than once a week)
- Patient at risk of infectious endocarditis
- Patients unable to answer questions
- Uncooperative patient

The clinical trial is being conducted with the collaboration of three French hospital centers: Hospital Center Emile Roux (Le Puy en Velay, France), Clinic of the Protestant Infirmary (Lyon, France) and Intercommunal Hospital Center (Mont de Marsan, France).

(Continued on next page)

* Correspondence: florence.carrouel@univ-lyon1.fr

¹University of Lyon, University Claude Bernard Lyon 1, Laboratory "Systemic Health Care", EA4129, 69008 Lyon, France

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Intervention and comparator: Eligible participants will be allocated to one of the two study groups. Intervention group: patients perform a tri-daily mouthwash with mouthwash containing antivirals (β -cyclodextrin and Citrox[®]) for a period of 7 days. Control group: patients perform a tri-daily mouthwash with a placebo mouthwash for a period of 7 days.

Main outcomes: Primary Outcome Measures: Change from Baseline amount of SARS-CoV-2 in salivary samples at 4 and 9 hours, 1, 2, 3, 4, 5 and 6 days. Real-time PCR assays are performed to assess salivary SARS-CoV 2 viral load.

Secondary Outcome Measures: Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 6 days. Real-time PCR assays are performed to assess nasal SARS-CoV-2 viral load.

Randomisation: Participants meeting all eligibility requirements are allocated to one of the two study arms (mouthwash with β -cyclodextrin and Citrox[®] or mouthwash without β -cyclodextrin and Citrox[®]) in a 1:1 ratio using simple randomisation with computer generated random numbers.

Blinding (masking): Participants, doctors and nurses caring for participants, laboratory technicians and investigators assessing the outcomes will be blinded to group assignment.

Numbers to be randomised (sample size): Both the intervention and control groups will be composed of 103 participants, so the study will include a total of 206 participants.

Trial Status: The current protocol version is 6, August 4th, 2020. Recruitment began on April 6, 2020 and is anticipated to be complete by April 5, 2021.

As of October 2, 2020, forty-two participants have been included.

Trial registration: This trial was registered on 20 April 2020 at www.clinicaltrials.gov with the number [NCT04352959](https://clinicaltrials.gov/ct2/show/study/NCT04352959).

Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol." The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2)."

Keywords: COVID-19, Randomised controlled trial, protocol, mouthwash, β -cyclodextrin, citrox[®], salivary and real-time PCR

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13063-020-04846-6>.

Additional file 1. Full Study Protocol.

Additional file 2. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

Acknowledgements

Not applicable.

Authors' contributions

FC: Senior Coordinator; SV: Principal Investigator; MV: Senior Virologist; JMC: Technical Adviser; CD: Scientific Adviser; DB: Senior Consultant. All authors contributed in a similar way to the writing of the manuscript. The authors read and approved the final manuscript.

Funding

The funds for the study were provided by the Laboratory "Systemic Health Care", EA4129, University of Lyon, France. Curaden AG, Switzerland made a technical contribution for the production of the mouthwash samples and a financial contribution within the framework of an agreement with the promoter of the study (University Lyon) for the purchase of the salivary kits and for the hospital costs inherent to the study. Curaden AG has no role in the design of the study and the

collection, analysis and interpretation of data. It will be the same in writing the manuscript.

Availability of data and materials

Individual patient data will be kept confidential and no-account personal identifiers of the study participants disclosed to the public. Only principal study coordinator and clinical trial unit or its auditing team will have the access to the study data. To ensure confidentiality, data dispersed to project team members will be blinded of any identifying participant information.

Ethics approval and consent to participate

The study protocol has been approved by the ethics committee "Comité de Protection des Personnes Sud Mediterranee III", University Hospital Center of Nîmes, France. The first version was approved on 21th April 2020 (Reference: 2020.04.11 ter_20.04.06.46640). The amended version was accepted on September 1, 2020 (Reference: 2020.04.11 six_20.04.06.46640). The authors certify that this trial has received ethical approval from the appropriate ethical committee as described above. Prior to involvement in the trial, written informed consent will be obtained from participants.

Consent for publication

Not applicable.

Competing interests

DB declares having a consulting activity in health promotion for the funder. All other authors declare that they have no competing interests.

Author details

¹University of Lyon, University Claude Bernard Lyon 1, Laboratory "Systemic Health Care", EA4129, 69008 Lyon, France. ²National Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France. ³Open Rome (Organize and Promote Epidemiological Network), Paris, France.

Received: 21 October 2020 Accepted: 28 October 2020

Published online: 02 November 2020

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

